The Y220C mutation destabilizes the p53 protein, impairing its tumor-suppressive functions and contributing to cancer progression. It is estimated to occur in approximately 1-2% of all cancers ...

A kidney cancer cell nucleus is studded with aberrant nuclear speckles (orange). Normal healthy cells tend to have the speckles clustered toward the middle. Image credit: Kate Alexander (Cold Spring ...

These mutations may interfere with the normal binding of the p53 protein to both DNA and/or its protein partners without affecting others. As a result, this can lead to an imbalance in the signal ...

In cancer with mutations, the Y220C mutation destabilizes the p53 protein, impairing its tumor-suppressive functions and contributing to cancer progression.

Here calcium dependent protein kinase 1 is found to directly activate ... show that chromosome mis-segregation induces mTORC2- and ATR-mediated p53 activation through a mechanosensitive checkpoint ...

Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers ...

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and prim ...

A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and growth ... The role of tumor suppressor p53 in metabolism and energy regulation, and its implication in cancer and ...

zju.edu.cn Objective Raf kinase inhibitor protein (RKIP) appears to control cancer cell metastasis ... Mechanistically, RKIP enhances the induction of P53-upregulated modulator of apoptosis by ...

FMC-220 represents a groundbreaking advancement, with the potential to provide transformative benefits for patients with tumors harboring an important mutant of p53. Preclinical studies ...